Immuno-Oncology | Specialty

Dr. de Wit Discusses Findings With Pembrolizumab in NMIBC

November 17th 2018

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses findings with pembrolizumab (Keytruda) in non-muscle invasive bladder cancer.

Durvalumab Combo Misses OS Endpoint in Frontline Metastatic NSCLC

November 16th 2018

The frontline combination of durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival compared to standard chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. McDermott on an Analysis of the CheckMate-214 Study in RCC

November 14th 2018

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

Dr. Feldman on the Future of Durvalumab and Tremilimumab in NSCLC

November 14th 2018

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses the future of durvalumab (Imfinzi) and tremelimumab in non–small cell lung cancer (NSCLC).

Dr. Powles on Biomarkers for Immunotherapy in Bladder Cancer

November 14th 2018

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder cancer.

Dr. Choueiri on Biomarkers in RCC

November 14th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses biomarkers in renal cell carcinoma.

FDA Grants Atezolizumab Combo Priority Review for Frontline TNBC

November 13th 2018

The FDA has granted a priority review designation to a supplemental biologics license application for the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Kirkwood Helped Chart Course of Adjuvant Immunotherapy in Melanoma

November 12th 2018

In the 44 years since John M. Kirkwood, MD began his career, he has seen melanoma become a growing field of research.

Rosenberg Reflects on Immunotherapy Developments in Urothelial Carcinoma

November 10th 2018

Jonathan E. Rosenberg, MD, discusses the extended follow-up of the CheckMate-032 study, as well as the future of immunotherapy in urothelial carcinoma.

Immunotherapy Approval Offers New Hope in CSCC

November 9th 2018

Treatment for cutaneous squamous cell carcinoma (CSCC) took a great leap forward in September 2018 with the PD-1 inhibitor cemiplimab becoming the first agent specifically approved by the FDA for advanced CSCC.

Personalized Immunotherapy Combinations on Horizon

November 9th 2018

Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment.

Halmos Highlights Advances in Squamous NSCLC

November 7th 2018

Balazs Halmos, MD, discusses the latest developments in the treatment paradigm for patients with squamous cell non–small cell lung cancer.

Dr. Meeks on Mutations Associated With T1 Progression in Bladder Cancer

November 6th 2018

Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the mutations associated with T1 progression in bladder cancer.

Lead Investigator Highlights Pembrolizumab Potential in BCG-Resistant Bladder Cancer

November 2nd 2018

Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in the non–muscle invasive bladder cancer patient population.

Immunotherapy Combinations Taking Shape in RCC

November 1st 2018

Asim Amin, MD, discusses the current role of checkpoint inhibitors in advanced renal cell carcinoma and where the future is heading in this space.

Dr. Burgess on Immunotherapy in Prostate Cancer

November 1st 2018

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the role of immunotherapy in prostate cancer.

Expert Highlights Immunotherapy/Chemotherapy Combos in TNBC

October 31st 2018

The efficacy of combination therapy with a checkpoint inhibitor and chemotherapy has been proved in the triple-negative breast cancer space, and the additive and early toxicity may be worth the survival benefit, according to Lisa A. Carey, MD.

Dr. Camidge on the FDA Approval of Pembrolizumab for Squamous NSCLC

October 31st 2018

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the FDA approval of first-line pembrolizumab (Keytruda) in metastatic squamous non–small cell lung cancer regardless of PD-L1 expression.

FDA Approves Frontline Pembrolizumab Regimen for Squamous NSCLC

October 31st 2018

The FDA has approved first-line pembrolizumab for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer.

Dr. Amin on Toxicities With Immunotherapy/TKI Combinations in RCC

October 30th 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses how to manage toxicities associated with immunotherapy and tyrosine kinase inhibitor combinations in renal cell carcinoma.